FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine

FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine

Publication date: Feb 10, 2025

The FDA’s approval marks a key milestone, paving the way for the Phase 1 trial to launch this spring. The trial will be conducted and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Concepts Keywords
Biotechnology Approval
Drug Clinical
Greenlights Covid
Spring Developed
Fda
Greenlights
Nasal
National
Ocugen
Phase
Trial
Vaccine
Washington

(Visited 1 times, 1 visits today)